Daiichi Sankyo Co., Ltd
., a top 20 pharmaceutical company headquartered in Japan, is expanding its use of
’ (NASDAQ: MDSO) cloud-based platform to support clinical trials conducted by its division in China. A long-time Medidata customer, Daiichi Sankyo will bring Medidata’s industry-leading applications for electronic data capture (EDC) and clinical data management (CDM) and randomization and trial supply management (RTSM) to its expanding clinical work in China. Daiichi Sankyo’s investment in the
Medidata Clinical Cloud
™ for its China division is expected to streamline trial activities, improve the efficiency of data capture and increase the productivity of site users and clinical monitors.
By adopting Medidata’s industry-leading data capture, management and reporting solution (
) in conjunction with its agile randomization and trial supply management solution (
), Daiichi Sankyo will have access to a single cloud-based platform that provides a unified environment in which site staff will conduct patient randomization, supply dispensing and clinical data capture, as well as enabling collaboration and insightful metrics visibility for the whole research team.
Daiichi Sankyo chose the Medidata platform for its expansion in China based on the improvements realized from its large-scale use of the Medidata platform since 2005.
Medidata Services Partner
Tigermed, a leading contract research organization (CRO), was involved in the selection and implementation of the Medidata platform for the China-based work.
“Medidata and Daiichi Sankyo have a long and fruitful relationship as collaborators, and we are delighted they have asked us to provide the efficient, effective and modern infrastructure needed for their clinical development programs in China,” said Glen de Vries, president, Medidata Solutions. “Organizations like Daiichi Sankyo that leverage innovative clinical technologies will be the leaders in bringing new life-enhancing treatments to market.”